The US pharmaceutical giant will pay USD 330 million upfront, with the potential for a further USD 2.3 billion in milestone payments, for the rights to develop and commercialise three in vivo CAR-T programmes outside Greater China.
The programmes, which target autoimmune diseases, are currently in “pre-IND” development.